Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. J&J collaborates with Merck to launch diabetes drug in China
  2. Salix to co-promote first approved non-opioid for opioid withdrawal
  3. EBOS Group achieves Australian pharmaceutical distribution deal
  4. Celgene and Skyhawk initiate five-year collaboration for neurological diseases
  5. Kaleido ends oversubscribed funding round at $101m

Company A-Z

Latest Content

Salix to co-promote first approved non-opioid for opioid withdrawal

Salix Pharmaceuticals’ subsidiary Valeant Pharmaceuticals has been granted exclusive rights to co-promote US WorldMed’s Lucemyra, which is the first non-opioid to be approved by the US Food and Drug Administration (FDA) to help manage abrupt opioid withdrawal. The financial terms of the deal were not disclosed in Salix’s announcement.

Kaleido ends oversubscribed funding round at $101m

Microbiome startup Kaleido Biosciences has closed its oversubscribed Series C financing round at $101m. Investment came from Fidelity Management, Invus, as well as a subsidiary of Abu Dhabi Investment Company and Flagship Pioneering, Kaleido’s founder.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top